Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases... Show more
ALT is expected to report earnings to rise 15.46% to -30 cents per share on August 07
Q2'25
Est.
$-0.30
Q1'25
Beat
by $0.12
Q4'24
Beat
by $0.01
Q3'24
Beat
by $0.04
Q2'24
Est.
$-0.35
The last earnings report on May 13 showed earnings per share of -25 cents, beating the estimate of -37 cents. With 2.27M shares outstanding, the current market capitalization sits at 442.84M.